CBD vs THC: Chemistry, the High, Legal Status, Drug Tests and Safety

The core difference in CBD vs THC is intoxication. Both are cannabinoids made by the cannabis plant, and both have the same chemical formula, but their atoms are arranged differently. THC (delta-9-tetrahydrocannabinol) activates the brain’s CB1 receptors and causes the high linked to marijuana; the CDC describes it as impairing or mind-altering. CBD (cannabidiol) binds those receptors only weakly and, by itself, does not cause a high. Federal hemp rules are written around THC content, and drug tests look for THC, not CBD.

Peptide Labs sells hemp-derived CBD products. This guide is general information as of September 30, 2026, not medical or legal advice.

CBD vs THC at a glance

The main differences, side by side:

Same formula, different shape

PubChem lists both cannabidiol and delta-9-THC with the molecular formula C21H30O2: 21 carbon atoms, 30 hydrogen atoms and 2 oxygen atoms. The difference is in how those atoms connect. THC has three joined rings, one of them a closed oxygen-containing ring called a pyran ring. In CBD that ring is open. A 2025 study in Nature Communications on how THC-type compounds bind the CB1 receptor notes that opening the pyran ring gives cannabidiols, which have weaker receptor affinity and psychoactivity than the THC class.

The plant actually makes the acid forms THCA and CBDA from a shared starting molecule, CBGA, and heat or light later turns those acids into THC and CBD, according to a 2021 review in the Journal of Cannabis Research. That is why THCA now counts toward total THC under federal hemp law. Our guide to CBG, CBN and CBC covers the other cannabinoids on this pathway.

Why THC causes a high and CBD does not

The body’s endocannabinoid system includes CB1 receptors, found mainly in the brain and nervous system, and CB2 receptors, found mainly in immune cells. THC partly activates CB1, and that activity is linked to its effects on the brain. The CDC says cannabis affects the parts of the brain responsible for memory, learning, attention, decision making, coordination, emotions and reaction time, and that it can slow reactions and distort perception while driving. The CDC also estimates that about 3 in 10 people who use cannabis have cannabis use disorder, with higher risk for those who start young or use often.

CBD behaves differently. In a human abuse-potential study described in the Epidiolex prescribing information, recreational drug users given purified CBD, even at the highest amounts tested, rated drug liking within the placebo range, while dronabinol (synthetic THC) produced large increases. The same label says CBD does not appear to act through cannabinoid receptors for its approved use. Not intoxicating is not the same as no effect, though: the FDA lists sleepiness, digestive upset and mood changes among possible CBD side effects.

Legal status: why the hemp definition matters

Cannabis that meets the legal definition of hemp is not a controlled substance; cannabis that does not is marijuana. Since the 2018 farm bill, hemp has meant cannabis with no more than 0.3% delta-9 THC by dry weight, which is how CBD products with trace THC reached store shelves.

That definition is changing. The timeline below matches our detailed guide to the 2026 hemp ban:

• November 12, 2025: Congress rewrote the hemp definition in P.L. 119-37. Hemp will be measured by total THC, including THCA, still capped at 0.3% by dry weight; finished products may contain no more than 0.4 mg of total THC and THC-like cannabinoids per container; and cannabinoids synthesized or converted outside the plant are excluded.
• September 2, 2026: H.R. 6500 was signed, moving the start date for most of the change from November 12 to December 11, 2026.
• November 12, 2026: cannabinoids that the cannabis plant cannot naturally produce still lose hemp status on the original date.
• December 11, 2026: the rest of the new definition takes effect unless Congress acts again.

CBD itself is not banned by this change. What will matter is how much total THC a product holds per container and how its cannabinoids were made. Marijuana, meanwhile, remains in Schedule I of the Controlled Substances Act, except for two categories the DEA moved to Schedule III effective April 28, 2026: marijuana in FDA-approved drug products and marijuana covered by a state medical marijuana license. A broader rescheduling decision was still pending in late September 2026. State laws on both hemp and marijuana vary and run on their own timelines.

FDA status: Epidiolex, dronabinol and CBD supplements

On June 25, 2018, the FDA approved Epidiolex, a purified CBD oral solution. It is a prescription drug, and its label now covers seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in patients 1 year and older. It remains the only FDA-approved drug made of CBD. On the THC side, the FDA has approved dronabinol (Marinol and Syndros), a synthetic form of THC, and nabilone (Cesamet), a synthetic compound with a structure similar to THC.

Over-the-counter CBD products are a different matter. The FDA has concluded that THC and CBD products are excluded from the dietary supplement definition, and it does not allow CBD to be added to food, because CBD is the active ingredient in an approved drug and was studied as a drug first. In January 2023 the agency said its existing food and supplement rules were not appropriate for CBD and that it would work with Congress on a new approach. As a result, CBD products are not FDA-approved and are not reviewed by the FDA for safety or labeling before sale.

Safety: what is known about CBD and THC

The FDA’s consumer guidance and the Epidiolex prescribing information list these safety facts for CBD:

• Liver. CBD can cause liver injury. In Epidiolex patients, liver enzyme elevations were more likely with higher amounts and with the seizure medicine valproate, and the label calls for liver blood tests before starting.
• Drug interactions. CBD is processed by liver enzymes (CYP3A4 and CYP2C19) and can change levels of medicines that use several of the same pathways, such as clobazam. Ask a pharmacist before combining CBD with any medicine.
• Drowsiness. Sleepiness is more likely with alcohol or other sedating drugs; the Epidiolex label advises against driving until you know how it affects you.
• Other effects. The FDA lists diarrhea, decreased appetite, irritability and agitation, and reports male reproductive toxicity in animal studies whose meaning for people is not yet clear.
• Pregnancy. Based on animal data, the Epidiolex label says CBD may cause fetal harm.

For THC, the main concerns are impairment of memory, coordination and reaction time, risks while driving, and cannabis use disorder, as described by the CDC. Hemp products labeled as full spectrum contain some THC, and some of their labels warn about drowsiness, impairment and driving.

Drug tests: THC is what they look for

Standard workplace drug tests screen for THC and its metabolite THC-COOH, not CBD. A CBD product can still lead to a positive result if it contains THC, and a test cannot tell whether that THC came from marijuana or hemp. Labels are not always accurate: when researchers tested 84 CBD products bought online for a 2017 JAMA study, only 31% contained the amount of CBD on the label, and THC was found in 18 of them. Our guide to whether CBD shows up on a drug test explains cutoffs and how to lower the risk.

How much THC is in a CBD product?

It depends on the extract type. Full-spectrum products keep the plant’s natural THC; broad-spectrum products have THC removed but keep other cannabinoids; isolate is purified CBD. Our comparison of full spectrum vs broad spectrum vs CBD isolate covers each in detail. Two examples from our store show the range:

• Medterra Daily Relief CBD Isolate Oil contains CBD isolate in organic MCT oil, and Medterra states its isolate products contain zero THC.
• cbdMD Full Spectrum CBD Tinctures contain a small amount of hemp-derived THC; the label warns that use may result in a positive drug test and advises against driving after use.

Whichever you consider, check the batch certificate of analysis for delta-9 THC and THCA, and compare spectrum and lab reports across our CBD category. Our guide on how to read a CBD certificate of analysis shows where to look.

Frequently Asked Questions

This article is general information as of September 30, 2026, not medical or legal advice. Questions? Contact us. CBD products sold at Peptide Labs are hemp-derived and are not FDA-approved drugs. The FDA has not approved CBD as a dietary supplement or food ingredient, and hemp product rules vary by state. Check your state’s rules, follow each product label and talk to a healthcare provider before using CBD if you take medicines, are pregnant or nursing, or have a medical condition.

Last reviewed September 2026.

Related guides: Hemp Ban 2026: What the New Federal Hemp Definition Means for CBD, THCA and Delta-8, Does CBD Show Up on a Drug Test?, Full Spectrum vs. Broad Spectrum vs. CBD Isolate: What’s the Difference?, CBD Drug Interactions: Blood Thinners, Liver Enzymes and What to Ask, CBD Gummies vs Oil: Absorption, Label Amounts, Sugar and Softgels, Is CBD Legal? Federal Law, State Rules and 2026 Changes, THC vs THCA: Decarboxylation, Total THC, Drug Tests and the 2026 Rules.